GlassScriptPhysician profile
Gerald G Kelty
NPI 1417989823
$5,848.70
in general payments reported to CMS, 2019-2025
49 companies · $737 in 2025
The $737 reported for 2025 was more than what 75% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $926 · 2022: $989 · 2023: $2,176 · 2024: $1,021 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,935 · Travel and Lodging: $999.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,934.79 |
| Travel and Lodging | $999.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Innovation | $1,355.11 | 2023 | Dysport |
| Abbvie INC. | $731.71 | 2021-2025 | |
| Lilly USA, LLC | $314.73 | 2022-2024 | Mounjaro, Jardiance, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.98 | 2021-2025 | Jardiance, Synjardy |
| Novo Nordisk INC | $228.14 | 2021 | |
| Glaxosmithkline, LLC. | $221.18 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $219.98 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $177.89 | 2021-2025 | |
| Viiv Healthcare Company | $173.56 | 2022-2025 | Apretude |
| Amgen INC. | $162.04 | 2021-2025 | Repatha, Otezla, Evenity |
| Gilead Sciences, INC. | $142.60 | 2021-2025 | |
| Lucid Diagnostics INC. | $106.77 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $104.40 | 2022-2023 | Quviviq |
| Amarin Pharma, INC. | $99.57 | 2021 | |
| Astellas Pharma US INC | $98.50 | 2024-2025 | Veozah |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Kelty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.